Wall Street Journal: Bepi rovirsen late-stage trial results show near one-fifth achieved a functional cure in two studies
A new report highlighted promising late-stage clinical results for bepirovirsen, a drug candidate discussed by The Wall Street Journal. The company behind the therapy said the treatment helped nearly a fifth of patients reach what researchers describe as a “functional cure” in two separate late-stage clinical trials. Functional cure is typically used in viral disease… Read More »